ArticleMolecular biology reports2026
A comprehensive analysis of epigenetic mechanisms regulating inflammation-induced TNF-α gene expression by small-molecule inhibitor screening.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms and therapeutic prospects of DNA methylation-mucosal innate immunity crosstalk in inflammatory bowel disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiologic therapies targeting TNF-α in inflammatory and autoimmune diseases underscore its central role in pathological inflammation. Epigenetic mechanisms are increasingly recognized as critical modulators of disease-associated gene expression, and advancing epigenetic-based therapeutics requires deeper insight into the transcriptional networks governing inflammatory responses. Here, we investigate the epigenetic regulation of inflammation-induced TNF-α transcription and identify lead compounds that suppress TNF-α expression in human macrophages. METHODS AND
resultsA small-molecule epigenetic inhibitor screen comprising 152 compounds was performed to assess their effects on LPS-induced TNF-α transcription in THP-1 monocyte-derived macrophages. TNF-α mRNA and protein levels were quantified using qRT-PCR and ELISA, respectively. The screen identified 20 potent inhibitors of TNF-α expression, representing six major classes of epigenetic regulators: HATs, BRDs, HDACs, HDMs, PRMT1, and PLK1. Protein-protein interaction network analysis revealed extensive crosstalk between these targets and key inflammatory signaling pathways, including NF-κB and MAPK. Follow-up validation of the top 10 candidates demonstrated dose-dependent suppression of TNF-α at both transcriptional and protein levels. These compounds also exhibited broad anti-inflammatory activity, suppressing IL-1β, IL-6, IL-8, IL-17A, and CCL2 expression, and showed cross-species efficacy in human (THP-1) and mouse (RAW264.7) macrophages. NF-κB reporter assays further indicated that their inhibitory effects are mediated, at least in part, through blockade of NF-κB activation.
conclusionsThis study identifies a regulatory network of epigenetic modifiers controlling TNF-α transcription and reveals conserved mechanisms governing inflammatory gene expression. The validated lead compounds possess potent anti-inflammatory properties and hold strong potential for therapeutic repurposing as modulators of TNF-α-driven inflammatory diseases.
Indexed as
Identifiers
41632348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.